ZLAB
Zai Lab Limited
27.29
USD
This page is just a preview of the data found in TrendSpider’s full version
Zai Lab Limited stock is down -3.09% since 30 days ago. The next earnings date is Feb 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 December’s closed higher than November. In the last 5 Unusual Options Trades, there were 3 PUTs, 2 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 23 Oct 15:49 | 15 Dec, 2023 | 25.00 | 136 | ||
| 27 Oct 16:20 | 15 Dec, 2023 | 22.50 | 4 | ||
| 08 Nov 15:14 | 15 Dec, 2023 | 35.00 | 13 | ||
| 08 Nov 20:12 | 15 Mar, 2024 | 30.00 | 7 | ||
| 24 Nov 17:22 | 21 Jun, 2024 | 25.00 | 1 |
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia. It also develops Odronextamab, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer
